VERU INC (VERU)

US92536C1036 - Common Stock

0.6491  +0.02 (+3.2%)

After market: 0.6699 +0.02 (+3.2%)

Fundamental Rating

2

Overall VERU gets a fundamental rating of 2 out of 10. We evaluated VERU against 36 industry peers in the Personal Care Products industry. While VERU seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, VERU is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VERU has reported negative net income.
In the past year VERU has reported a negative cash flow from operations.
VERU had negative earnings in 4 of the past 5 years.
VERU had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

VERU's Return On Assets of -62.57% is on the low side compared to the rest of the industry. VERU is outperformed by 88.57% of its industry peers.
With a Return On Equity value of -116.97%, VERU is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

VERU's Gross Margin of 34.66% is on the low side compared to the rest of the industry. VERU is outperformed by 77.14% of its industry peers.
VERU's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VERU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%

More info and screens

4

2. Health

2.1 Basic Checks

VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
VERU has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VERU has more shares outstanding
Compared to 1 year ago, VERU has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -6.14, we must say that VERU is in the distress zone and has some risk of bankruptcy.
VERU's Altman-Z score of -6.14 is on the low side compared to the rest of the industry. VERU is outperformed by 91.43% of its industry peers.
VERU has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
VERU's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. VERU outperforms 48.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -6.14
ROIC/WACCN/A
WACC8.72%

2.3 Liquidity

A Current Ratio of 2.97 indicates that VERU has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.97, VERU belongs to the best of the industry, outperforming 82.86% of the companies in the same industry.
VERU has a Quick Ratio of 2.62. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.62, VERU belongs to the top of the industry, outperforming 82.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.62

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.01% over the past year.
The Revenue has been growing slightly by 3.62% in the past year.
The Revenue for VERU have been decreasing by -11.89% on average. This is quite bad
EPS 1Y (TTM)76.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.47%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%72.36%

3.2 Future

VERU is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.05% yearly.
Based on estimates for the next years, VERU will show a very strong growth in Revenue. The Revenue will grow by 63.28% on average per year.
EPS Next Y3.36%
EPS Next 2Y-11.93%
EPS Next 3Y-5.51%
EPS Next 5Y3.05%
Revenue Next Year-7.3%
Revenue Next 2Y-13.77%
Revenue Next 3Y-6.78%
Revenue Next 5Y63.28%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as VERU's earnings are expected to decrease with -5.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.93%
EPS Next 3Y-5.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERU INC

NASDAQ:VERU (12/20/2024, 7:36:02 PM)

After market: 0.6699 +0.02 (+3.2%)

0.6491

+0.02 (+3.2%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)12-05 2024-12-05/amc
Earnings (Next)02-06 2025-02-06/bmo
Inst Owners37.79%
Inst Owner Change-0.91%
Ins Owners10.62%
Ins Owner Change0%
Market Cap95.02M
Analysts81.82
Price Target3.47 (434.59%)
Short Float %10.72%
Short Ratio13.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)47.04%
Min Revenue beat(2)10.75%
Max Revenue beat(2)83.32%
Revenue beat(4)3
Avg Revenue beat(4)22.02%
Min Revenue beat(4)-41.15%
Max Revenue beat(4)83.32%
Revenue beat(8)4
Avg Revenue beat(8)1.72%
Revenue beat(12)6
Avg Revenue beat(12)-8.13%
Revenue beat(16)8
Avg Revenue beat(16)-3.95%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)37.5%
EPS NQ rev (3m)37.5%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-56.5%
Revenue NQ rev (3m)-56.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.63
P/FCF N/A
P/OCF N/A
P/B 2.94
P/tB 3.74
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.12
BVpS0.22
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.66%
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.04%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.62
Altman-Z -6.14
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)217.78%
Cap/Depr(5y)171.54%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.47%
EPS Next Y3.36%
EPS Next 2Y-11.93%
EPS Next 3Y-5.51%
EPS Next 5Y3.05%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%72.36%
Revenue Next Year-7.3%
Revenue Next 2Y-13.77%
Revenue Next 3Y-6.78%
Revenue Next 5Y63.28%
EBIT growth 1Y61.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.36%
OCF growth 3YN/A
OCF growth 5YN/A